Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Strober

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
The Journal of Clinical Investigation|July 1, 2025
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flaresJames G Krueger, Mrinal K Sarkar, Mark G Lebwohl, et al.
The New England Journal of Medicine|October 1, 2015
Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisMark Lebwohl, Bruce Strober, Alan Menter, et al.
Journal of the American Academy of Dermatology|August 2, 2020
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measuresCraig A Elmets, Neil J Korman, Elizabeth Farley Prater, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
The Journal of Clinical Investigation|July 1, 2025
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flaresJames G Krueger, Mrinal K Sarkar, Mark G Lebwohl, et al.
The New England Journal of Medicine|October 1, 2015
Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisMark Lebwohl, Bruce Strober, Alan Menter, et al.
Journal of the American Academy of Dermatology|August 2, 2020
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measuresCraig A Elmets, Neil J Korman, Elizabeth Farley Prater, et al.
Pageof 13